In a recent study published in the EClinicalMedicine , a group of researchers evaluated the 12-month neurological and psychiatric outcomes of semaglutide use in patients with type 2 diabetes mellitus (T2DM) (Chronic high blood sugar due to insulin resistance or deficiency) using a propensity-score matched cohort. Semaglutide, a glucagon-like peptide 1 receptor agonist (GLP1-RA) approved for T2DM and obesity, is a 2023 scientific breakthrough. Healthcare spending on GLP1-RAs is set to rise with new uses and formulations.
Randomized controlled trials (RCTs) show semaglutide's effectiveness in metabolic and cardiovascular outcomes. Studies indicate potential neurobiological benefits for neurological, psychiatric, and substance use disorders. However, safety reviews by the European Medicines Agency (EMA) and the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA), triggered by mood change reports, raise concerns.
Further research is needed to clarify the neuropsychiatric safety and overall brain health impact of semaglutide and GLP1-RAs in T2DM patients. The present study adheres to the Reporting of Studies Conducted using Observational Routinely-collected Health Data (RECORD) guidelines. Utilizing the TriNetX United States (US) Collaborative Network, a large-scale federated database, this study analyzed anonymized electronic health records (EHRs) of over 100 million patients across 62 healthcare organizations in the US.
This platform includes patient d.
